{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-23-000012","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.575589+00:00","generated_at":"2026-06-19T10:09:07.089890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Labcorp reports Q4 2022 revenue $3.7B, GAAP EPS $0.86 (vs $5.75 YoY), provides FY2023 adjusted EPS guidance $16-$18","bullets":["Q4 rev $3.67B (-9.4% YoY); GAAP diluted EPS $0.86 vs $5.75; adj EPS $4.14 vs $6.77.","Full-year 2022 rev $14.88B (-7.7%); adj EPS $19.94 vs $28.52; free cash flow $1.47B.","Diagnostics base business organic +6.4%; Drug Development backlog $16.3B (+8.9%), net book-to-bill 1.27.","FY2023 guidance: total rev growth 1-4%, base business 8.5-10.5%; adj EPS $16-$18; FCF $1.0-$1.2B.","Spin-off of Clinical Development (Fortrea) on track for mid-2023; Board authorized additional $1B share buyback; $0.72 dividend payable Mar 13."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-23-000012","json":"https://secwatch.observer/filing/0000920148-23-000012.json","markdown":"https://secwatch.observer/filing/0000920148-23-000012.md","text":"https://secwatch.observer/filing/0000920148-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/lh-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T10:09:07.089890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac548ea49def940a15b97d2e4c08f12ecd1280ed","claim":"LABCORP HOLDINGS INC. updated its guidance (initiated).","evidence_excerpt":"Full-Year 2023 Guidance: Adjusted EPS of $16.00 to $18.00 and Free Cash Flow of $1.0 billion to $1.2 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"fbe0e926bf128a26943fff23f2d4021d52b7b325","claim":"LABCORP HOLDINGS INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue $14.88 billion, net income $1.28 billion, EPS $13.97.","evidence_excerpt":"for share repurchases, bringing the total available authorization to approximately $1.53 billion. 2 Consolidated Results Fourth Quarter Results Revenue for the quarter was $3.67 billion, a decrease of (9.4%) from $4.06 billion in the fourth quarter of 2021. The decrease was due to organic revenue of (9.4%) and foreign currency translation of (1.3%), partially","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended Dec. 31, 2022"},{"label":"Revenue","value":"$14.88 billion"},{"label":"Net income","value":"$1.28 billion"},{"label":"EPS","value":"$13.97"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fbe0e926bf128a26943fff23f2d4021d52b7b325","claim":"LABCORP HOLDINGS INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue $14.88 billion, net income $1.28 billion, EPS $13.97.","evidence_excerpt":"Revenue was $14.88 billion, a decrease of (7.7%) from $16.12 billion in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended Dec. 31, 2022"},{"label":"Revenue","value":"$14.88 billion"},{"label":"Net income","value":"$1.28 billion"},{"label":"EPS","value":"$13.97"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}